Delivery of Paclitaxel and Everolimus in HER2-Targeted Polymeric Nanoparticles to HER2 Positive Metastatic Breast Cancer

Loujin Houdaihed

University of Toronto

Loujin Houdaihed is a PhD Candidate in Christine Allen lab at the department of Pharmaceutical Sciences, University of Toronto. She received a B.Sc. degree in Pharmacy and Pharmaceutical Chemistry from Damascus University, Syria in 2011. She started her M.Sc. degree at Univeristy of Toronto in 2014 and successfully transferred to the PhD program in 2016. Loujin is developing actively targeted-nano drug formulations of combination therapies for breast cancer. She is the recipient of the CIHR Doctoral Research Award and the Centre for Pharmaceutical Oncology Scholarship (CPO) 2015-2016.


Introduction: The combination of paclitaxel (PTX) and trastuzumab (TmAb) has been the first line therapy for metastatic HER2+ breast cancer (BC) for nearly two decades. However, the majority of patients develop TmAb resistance... [ view full abstract ]


  1. Loujin Houdaihed (University of Toronto)
  2. James Evans (University of Toronto)
  3. Christine Allen (University of Toronto)

Topic Areas

Targeted drug delivery and nanocarriers , Nanomedicine for cancer diagnosis & therapy


PS3 » Poster Session (13:30 - Wednesday, 27th September, Gallery)

Presentation Files

The presenter has not uploaded any presentation files.